# US 2021/0330586 A1 · Azole comopund ophthalmic preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330586 A1
- Document ID: US20210330586A1
- Status: Published application
- Kind: A1
- Application number: 17/367,863
- Filed: 2021-07-06
- Published: 2021-10-28
- Earliest claimed: 2016-08-24
- Assignees: Qinyuan ZHENG; Biotool, LLC; Inhibio Bioscience Pte. Ltd.
- Applicants: Biotool, LLC; Inhibio Bioscience Pte. Ltd.
- Inventors: Qinyuan ZHENG; Zeyidan JIAPAER
- Web page: https://patentgrep.com/patent/US20210330586A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophthalmic diseases. The ophthalmic preparation contains the azole compound at a concentration of 0.005-400 μM.

## Claims

### Claim 1

A method for preventing or treating an ocular lens disease, which comprises non-invasively administering an ophthalmic preparation to an eye or two eyes of a subject in need thereof;
the ophthalmic preparation comprises: (a) a pharmaceutically acceptable carrier, and (b) an azole compound as a first active ingredient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the concentration of the azole compound in the ophthalmic preparation is from 0.005 to 400 μM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ophthalmic preparation is selected from the group consisting of eye drop, an emulsion, gel, eye ointment, sustained-release microsphere, intraocular sustained-release graft, and ocular sustained-release drug film.

### Claim 4 (depends on 1)

The method of claim 1, wherein the azole compound is selected from the group consisting of econazole, isoconazole, bifonazole, clotrimazole, aripiprazole, ketoconazole, fluconazole, phenylimidazole, miconazole, cyproconazole, triazolol, tebuconazole, propiconazole, VFV.

### Claim 5 (depends on 1)

The method of claim 1, wherein in the ophthalmic preparation, the concentration of the azole compound is from 0.01 to 200 μM, preferably from 0.025 to 100 μM, more preferably from 0.05 to 50 μM; most preferably from 0.5 to 10 μM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ophthalmic preparation further comprises: (c) a second active ingredient, wherein the second active ingredient is selected from the group consisting of: a steroid compound, glucocorticoid compound, antibiotics, and combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the second active ingredient is lanosterol compound.

### Claim 8 (depends on 7)

The method of claim 7, wherein the concentration of the lanosterol compound is from 10 to 200 mM, preferably from 15 to 150 mM, more preferably from 20 to 50 mM; most preferably from 20 to 30 mM.

### Claim 9 (depends on 7)

The method of claim 7, wherein the lanosterol compound is lanosterol.

### Claim 10 (depends on 1)

The method of claim 1, the ophthalmic preparation is an aqueous solution for ocular administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ocular lens disease is selected from the group consisting of cataract, presbyopia, and combinations thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cataract is selected from the group consisting of: senile cataract, congenital cataract, traumatic cataract, and concurrent cataract.

### Claim 13 (depends on 1)

The method of claim 1, wherein the “non-invasively administering” means dripping into the eye.

### Claim 14

A method for preventing or treating human or non-human mammal ocular lens disease, which comprises administering an ophthalmic preparation;
the ophthalmic preparation comprises: (a) a pharmaceutically acceptable carrier, and (b) an azole compound as a first active ingredient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the concentration of the azole compound in the ophthalmic preparation is from 0.005 to 400 μM.

### Claim 16 (depends on 14)

The method of claim 14, wherein the ocular lens disease is selected from the group consisting of: cataract, presbyopia, and combinations thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cataract is selected from the group consisting of: senile cataract, congenital cataract, traumatic cataract, and concurrent cataract.

### Claim 18

A method for preventing or treating an ocular lens disease, which comprises the following steps: orally administering an oral preparation or administering an injection formulation to the eye(s) of a subject in need thereof, wherein the oral preparation or injection formulation comprises (a1) a pharmaceutically acceptable carrier, and (b1) an azole compound as a first active ingredient; wherein the concentration of the azole compound in the preparation is 0.01-90 wt %.

### Claim 19 (depends on 19)

The method of claim 19, wherein the ocular lens disease is selected from the group consisting of: cataract, presbyopia, and combinations thereof.

### Claim 20 (depends on 20)

The method of claim 20, wherein the cataract is selected from the group consisting of: senile cataract, congenital cataract, traumatic cataract, and concurrent cataract.
